Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

CAR-T Meeting 2020 | Exciting data from the 2nd European CAR T-Cell Meeting

Robin Sanderson • 30 Jan 2020
CAR-T Meeting 2020
Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T Lisocabtagene maraleucel
ZUMA-1

Robin Sanderson, MBChB, MRCP, FRCPath, King’s College Hospital NHS Foundation Trust, London, UK, outlines the updates presented at the 2nd European CAR T-Cell Meeting in Sitges, Spain. Dr Sanderson highlights the ZUMA-1 trial and axicabtagene ciloleucel for mantle cell lymphoma. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.

More from Robin Sanderson

Lymphoma Sessions: CAR-T and lymphoma treatment in the UK
Robin Sanderson et al. • 18 May 2022
CAR T-cell therapy at King’s College Hospital 0:34
CAR T-cell therapy at King’s College Hospital
Robin Sanderson • 30 Jan 2020
The CAR T-cell therapy referral pathway at King’s College London 1:00
The CAR T-cell therapy referral pathway at King’s College London
Robin Sanderson • 30 Jan 2020
CAR-T in the UK: updates from King’s College Hospital 2:47
CAR-T in the UK: updates from King’s College Hospital
Robin Sanderson • 10 Jul 2019

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals